Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.66 |
| ▸ | ACHE | P22303 | 3/20 | 0.60 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14157348 | 0.98 | TAAR1 (0.64) | TAAR1ACHEDHFRMAOBDRD2 | |
| SCHEMBL25101090 | 0.86 | TAAR1 (0.62) | TAAR1ACHEMAOBDRD2DRD1 | |
| SCHEMBL756850 | 0.85 | DHFR (0.51) | TAAR1ACHEDHFRMAOBHCRTR1 | |
| SCHEMBL28121086 | 0.85 | TAAR1 (0.60) | TAAR1ACHEMAOBDRD2DRD1 | |
| SCHEMBL27987194 | 0.85 | TAAR1 (0.60) | TAAR1ACHEMAOBDRD2DRD1 | |
| SCHEMBL28121082 | 0.85 | TAAR1 (0.60) | TAAR1ACHEMAOBDRD2DRD1 | |
| SCHEMBL12881236 | 0.84 | ALOX5 (0.49) | TAAR1ACHEDHFRFFAR4 | |
| SCHEMBL1416835 | 0.82 | CYP4F2 (0.56) | TAAR1ACHEDHFRFFAR4 | |
| SCHEMBL14486728 | 0.82 | DHFR (0.46) | TAAR1ACHEDHFRFFAR4 | |
| SCHEMBL8053575 | 0.82 | FFAR4 (0.49) | TAAR1ACHEDHFRFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-09-27 | — | — | US | disclosed |
| EP-3356363-A1 | NEW IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS DUAL DYRK1/CLK1 INHIBITORS | Les Laboratoires Servier (FR) | 2018-08-08 | — | — | EP | disclosed |
| CN-104946241-A | One-dimensional organic semiconductor nanotube and its preparation method and use | CHINESE ACAD INST CHEMISTRY | 2015-09-30 | — | — | CN | disclosed |
| CN-101939326-B | Method for producing cycloplatinized platinum complexes, platinum complexes produced by said method, and the use thereof | RWTH AACHEN UNIVERSITY | 2013-06-05 | — | — | CN | disclosed |
| WO-2012170561-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | THE SCRIPPS RESEARCH INSTITUTE (T.S.R.I.) (US) | 2012-12-13 | — | — | WO | disclosed |
| CN-101939326-A | Method for producing cycloplatinized platinum complexes, platinum complexes produced by said method, and the use thereof | RWTH AACHEN | 2011-01-05 | — | — | CN | disclosed |
| EP-0540143-B1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| US-5714503-A | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 1998-02-03 | — | — | US | disclosed |
| US-5658907-A | THIOUREA VIRICIDES | MEDIVIR A/B (SE) | 1997-08-19 | — | — | US | disclosed |
| US-5593993-A | VIRICIDES FOR HTLV TREATMENT OF AIDS | MEDIVIR AB (SE) | 1997-01-14 | — | — | US | disclosed |
| US-5231181-A | PROCESS FOR THE PREPARATION OF (8AS,12AS,13AS)-DECAHYDROISOQUINO ((2,1-G) (1,6)-NAPHTHYRIDIN-8-ONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1993-07-27 | — | — | US | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
| EP-0505183-A2 | Process for the preparation of (8aS,12aS,13aS)-decahydroisoquino[2,1-g][1,6]-naphthyridin-8-one derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDH2, CYP4B1, RB1 | TAAR1 2324/4885ACHE 174/4885DHFR 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.